Story perspectives

Hundreds of GLP-1 NAION lawsuits consolidated in MDL 3163

By Drooid · Sep 25, 2026, 3:05 PM UTC · How we work

Summary

Story summary

U.S. plaintiffs have filed hundreds of lawsuits against Novo Nordisk and Eli Lilly alleging GLP-1 drugs cause NAION.
NAION is a rare, sudden, painless vision-loss condition affecting 2-10 per 100,000, mainly people 50+.
European regulators label NAION a very rare side effect of semaglutide, up to 1 in 10,000 cases.
The FDA is reviewing the link but has not added a NAION warning to U.S. labels.
100 New Jersey lawsuits since 2025 and others in Philadelphia were consolidated into MDL #3163, overseen by Judge Karen Spencer Marston.

1 of 1

Story summary

U.S. plaintiffs have filed hundreds of lawsuits against Novo Nordisk and Eli Lilly alleging GLP-1 drugs cause NAION.
NAION is a rare, sudden, painless vision-loss condition affecting 2-10 per 100,000, mainly people 50+.
European regulators label NAION a very rare side effect of semaglutide, up to 1 in 10,000 cases.
The FDA is reviewing the link but has not added a NAION warning to U.S. labels.
100 New Jersey lawsuits since 2025 and others in Philadelphia were consolidated into MDL #3163, overseen by Judge Karen Spencer Marston.